Alseres Pharmaceuticals, Inc. (ALSE)
USD 0.01
(100.0%)
USD 0.01
(100.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2013 | 385.47 Thousand USD | -60.08% |
| 2012 | 965.7 Thousand USD | 465.64% |
| 2011 | 170.72 Thousand USD | -62.93% |
| 2010 | 460.59 Thousand USD | -41.76% |
| 2009 | 790.81 Thousand USD | -6.44% |
| 2008 | 845.25 Thousand USD | -84.97% |
| 2007 | 5.62 Million USD | 137.4% |
| 2006 | 2.36 Million USD | -77.47% |
| 2005 | 10.51 Million USD | 313.23% |
| 2004 | 2.54 Million USD | -85.4% |
| 2003 | 17.43 Million USD | 104.42% |
| 2002 | 8.52 Million USD | -25.37% |
| 2001 | 11.42 Million USD | -44.83% |
| 2000 | 20.71 Million USD | 28.65% |
| 1999 | 16.1 Million USD | 30.89% |
| 1998 | 12.3 Million USD | -33.87% |
| 1997 | 18.6 Million USD | -29.01% |
| 1996 | 26.2 Million USD | 296.97% |
| 1995 | 6.6 Million USD | 78.38% |
| 1994 | 3.7 Million USD | -72.39% |
| 1993 | 13.4 Million USD | -28.72% |
| 1992 | 18.8 Million USD | -12.15% |
| 1991 | 21.4 Million USD | 67.19% |
| 1990 | 12.8 Million USD | 88.24% |
| 1989 | 6.8 Million USD | 88.89% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2014 Q2 | 279.02 Thousand USD | -23.44% |
| 2014 Q1 | 364.43 Thousand USD | -5.46% |
| 2013 FY | 385.47 Thousand USD | -60.08% |
| 2013 Q2 | 147.88 Thousand USD | -58.25% |
| 2013 Q4 | 385.47 Thousand USD | 181.63% |
| 2013 Q3 | 136.87 Thousand USD | -7.45% |
| 2013 Q1 | 354.24 Thousand USD | -63.32% |
| 2012 Q2 | 129.53 Thousand USD | -38.11% |
| 2012 FY | 965.7 Thousand USD | 465.64% |
| 2012 Q1 | 209.29 Thousand USD | 22.59% |
| 2012 Q3 | 1.02 Million USD | 687.59% |
| 2012 Q4 | 965.7 Thousand USD | -5.34% |
| 2011 Q1 | 393.34 Thousand USD | -14.6% |
| 2011 Q4 | 170.72 Thousand USD | -55.24% |
| 2011 Q3 | 381.41 Thousand USD | 10.91% |
| 2011 FY | 170.72 Thousand USD | -62.93% |
| 2011 Q2 | 343.89 Thousand USD | -12.57% |
| 2010 Q1 | 660.45 Thousand USD | -16.48% |
| 2010 Q3 | 563.28 Thousand USD | 10.61% |
| 2010 Q4 | 460.59 Thousand USD | -18.23% |
| 2010 FY | 460.59 Thousand USD | -41.76% |
| 2010 Q2 | 509.23 Thousand USD | -22.9% |
| 2009 Q3 | 958.44 Thousand USD | 35.14% |
| 2009 Q2 | 709.19 Thousand USD | -45.78% |
| 2009 Q4 | 790.81 Thousand USD | -17.49% |
| 2009 Q1 | 1.3 Million USD | 54.76% |
| 2009 FY | 790.81 Thousand USD | -6.44% |
| 2008 FY | 845.25 Thousand USD | -84.97% |
| 2008 Q4 | 845.25 Thousand USD | -63.54% |
| 2008 Q3 | 2.31 Million USD | -66.65% |
| 2008 Q2 | 6.95 Million USD | -1.03% |
| 2008 Q1 | 7.02 Million USD | 24.89% |
| 2007 Q2 | 3.72 Million USD | 51.54% |
| 2007 FY | 5.62 Million USD | 137.4% |
| 2007 Q4 | 5.62 Million USD | -42.36% |
| 2007 Q3 | 9.75 Million USD | 161.91% |
| 2007 Q1 | 2.45 Million USD | 3.77% |
| 2006 FY | 2.36 Million USD | -77.47% |
| 2006 Q4 | 2.36 Million USD | -0.87% |
| 2006 Q2 | 3.37 Million USD | -51.42% |
| 2006 Q1 | 6.94 Million USD | -33.97% |
| 2006 Q3 | 2.38 Million USD | -29.15% |
| 2005 FY | 10.51 Million USD | 313.23% |
| 2005 Q1 | 6.06 Million USD | 138.16% |
| 2005 Q2 | 3.63 Million USD | -40.08% |
| 2005 Q3 | 13.61 Million USD | 274.99% |
| 2005 Q4 | 10.51 Million USD | -22.78% |
| 2004 Q4 | 2.54 Million USD | -70.89% |
| 2004 FY | 2.54 Million USD | -85.4% |
| 2004 Q1 | 15.37 Million USD | -11.83% |
| 2004 Q2 | 11.19 Million USD | -27.16% |
| 2004 Q3 | 8.74 Million USD | -21.93% |
| 2003 FY | 17.43 Million USD | 104.42% |
| 2003 Q2 | 14.05 Million USD | -13.34% |
| 2003 Q3 | 12.2 Million USD | -13.14% |
| 2003 Q4 | 17.43 Million USD | 42.83% |
| 2003 Q1 | 16.21 Million USD | 90.13% |
| 2002 Q1 | 12.07 Million USD | 5.66% |
| 2002 Q3 | 10.7 Million USD | 13.18% |
| 2002 FY | 8.52 Million USD | -25.37% |
| 2002 Q4 | 8.52 Million USD | -20.31% |
| 2002 Q2 | 9.45 Million USD | -21.69% |
| 2001 Q2 | 16.04 Million USD | -15.58% |
| 2001 Q1 | 19.01 Million USD | -8.22% |
| 2001 Q4 | 11.42 Million USD | -18.93% |
| 2001 FY | 11.42 Million USD | -44.83% |
| 2001 Q3 | 14.09 Million USD | -12.17% |
| 2000 Q3 | 22.29 Million USD | -3.34% |
| 2000 Q2 | 23.06 Million USD | 41.01% |
| 2000 Q1 | 16.35 Million USD | 1.6% |
| 2000 FY | 20.71 Million USD | 28.65% |
| 2000 Q4 | 20.71 Million USD | -7.1% |
| 1999 FY | 16.1 Million USD | 30.89% |
| 1999 Q4 | 16.1 Million USD | -28.76% |
| 1999 Q3 | 22.6 Million USD | 33.73% |
| 1999 Q2 | 16.9 Million USD | -9.63% |
| 1999 Q1 | 18.7 Million USD | 52.03% |
| 1998 FY | 12.3 Million USD | -33.87% |
| 1998 Q1 | 16.5 Million USD | -11.29% |
| 1998 Q3 | 13.9 Million USD | -7.95% |
| 1998 Q4 | 12.3 Million USD | -11.51% |
| 1998 Q2 | 15.1 Million USD | -8.48% |
| 1997 Q4 | 18.6 Million USD | -7.46% |
| 1997 FY | 18.6 Million USD | -29.01% |
| 1997 Q3 | 20.1 Million USD | -8.64% |
| 1997 Q2 | 22 Million USD | -8.71% |
| 1997 Q1 | 24.1 Million USD | -8.02% |
| 1996 Q4 | 26.2 Million USD | -6.09% |
| 1996 Q3 | 27.9 Million USD | -3.13% |
| 1996 Q2 | 28.8 Million USD | 14.29% |
| 1996 FY | 26.2 Million USD | 296.97% |
| 1996 Q1 | 25.2 Million USD | 281.82% |
| 1995 Q4 | 6.6 Million USD | 3.13% |
| 1995 FY | 6.6 Million USD | 78.38% |
| 1995 Q1 | 3.1 Million USD | -16.22% |
| 1995 Q2 | 6.9 Million USD | 122.58% |
| 1995 Q3 | 6.4 Million USD | -7.25% |
| 1994 FY | 3.7 Million USD | -72.39% |
| 1994 Q4 | 3.7 Million USD | -19.57% |
| 1994 Q3 | 4.6 Million USD | -13.21% |
| 1994 Q2 | 5.3 Million USD | -48.04% |
| 1994 Q1 | 10.2 Million USD | -23.88% |
| 1993 Q2 | 27.7 Million USD | 97.86% |
| 1993 FY | 13.4 Million USD | -28.72% |
| 1993 Q1 | 14 Million USD | -25.53% |
| 1993 Q3 | 23.4 Million USD | -15.52% |
| 1993 Q4 | 13.4 Million USD | -42.74% |
| 1992 Q1 | 19 Million USD | -11.21% |
| 1992 Q3 | 11.2 Million USD | -25.83% |
| 1992 Q4 | 18.8 Million USD | 67.86% |
| 1992 FY | 18.8 Million USD | -12.15% |
| 1992 Q2 | 15.1 Million USD | -20.53% |
| 1991 Q1 | 12.9 Million USD | 0.78% |
| 1991 Q4 | 21.4 Million USD | 118.37% |
| 1991 FY | 21.4 Million USD | 67.19% |
| 1991 Q3 | 9.8 Million USD | 0.0% |
| 1990 Q4 | 12.8 Million USD | 0.0% |
| 1990 FY | 12.8 Million USD | 88.24% |
| 1989 FY | 6.8 Million USD | 88.89% |
| 1989 Q4 | 6.8 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -16587.056% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 80.315% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 96.348% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 30.183% |
| Rebus Holdings, Inc. | 5000.00 USD | -7609.42% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.704% |
| Qrons Inc. | 420.00 USD | -91678.81% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 49.981% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 98.621% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 19.787% |
| Skye Bioscience, Inc. | 11.94 Million USD | 96.772% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.008% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 94.661% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -404.847% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.64% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 73.082% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -432.676% |
| Mesoblast Limited | 667.9 Million USD | 99.942% |
| Marizyme, Inc. | 22.01 Million USD | 98.249% |
| Genus plc | 1.02 Billion USD | 99.963% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 71.622% |
| Pharming Group N.V. | 462.85 Million USD | 99.917% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 88.365% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 22.757% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 38.521% |
| ContraFect Corporation | 20.67 Million USD | 98.136% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 1.254% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -0.862% |
| IMV Inc. | 31.33 Million USD | 98.77% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 90.703% |
| MultiCell Technologies, Inc. | 126.22 USD | -305296.134% |
| ONE Bio Corp. | 70.08 Million USD | 99.45% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 58.979% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.7% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 10.711% |
| Q BioMed Inc. | 3.51 Million USD | 89.035% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 98.904% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -47.533% |
| Biomind Labs Inc. | 73.81 Thousand USD | -422.184% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.914% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 73.395% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 98.716% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 85.964% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 43.93% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 85.192% |
| GB Sciences, Inc. | 103.44 Thousand USD | -272.645% |
| Alpha Cognition Inc. | 2.45 Million USD | 84.28% |
| HST Global, Inc. | 1526.00 USD | -25160.223% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 60.983% |
| Halberd Corporation | 10.13 Thousand USD | -3704.866% |
| Enzolytics Inc. | 361.7 Million USD | 99.893% |
| Agentix Corp. | 261.39 Thousand USD | -47.469% |
| Resverlogix Corp. | 8.11 Million USD | 95.25% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 79.473% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.992% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.192% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 39.738% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1592.072% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 95.693% |
| AVAX Technologies, Inc. | 7.37 Million USD | 94.775% |
| Zenith Capital Corp. | 7410.00 USD | -5102.038% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.989% |
| Ember Therapeutics, Inc. | 184.00 USD | -209395.109% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -19.784% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -47.484% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 58.46% |
| Kadimastem Ltd | 2.3 Million USD | 83.27% |
| Helix BioMedix, Inc. | 3.02 Million USD | 87.258% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.269% |
| BioStem Technologies, Inc. | 14.56 Million USD | 97.353% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -575.152% |
| LadRx Corporation | 2.3 Million USD | 83.298% |
| Cell Source, Inc. | 195.17 Thousand USD | -97.504% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -9.008% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -9.008% |
| NovAccess Global Inc. | 62.24 Thousand USD | -519.25% |
| Affymax, Inc. | 7.44 Million USD | 94.821% |
| Itoco Inc. | 1.4 Million USD | 72.468% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -302.972% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -263.652% |
| Mobile Lads Corp. | 52.00 USD | -741190.385% |
| CytoDyn Inc. | 11.13 Million USD | 96.539% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -169.613% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -2055.878% |
| SYBLEU INC | 330.46 Thousand USD | -16.644% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 5.85% |
| International Stem Cell Corporation | 5.39 Million USD | 92.848% |
| Bioxytran, Inc. | 137.63 Thousand USD | -180.061% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 97.431% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 97.675% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -387.938% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 55.42% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 94.872% |
| Neutra Corp. | 2851.00 USD | -13420.554% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 98.81% |
| PureTech Health plc | 693.97 Million USD | 99.944% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 95.224% |
| IXICO plc | 15.84 Million USD | 97.567% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 95.346% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.627% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.885% |